Sareum Company Research (SAR)

Sareum has announced the publication of full Phase I clinical data for lead asset SDC-1801 (a TYK2/JAK1 inhibitor) in the British Journal of Clinical Pharmacology. We view the publication as an external validation of the programme, providing peer-reviewed confirmation of the safety, pharmacokinetic (PK) and pharmacodynamic (PD) profile previously reported by management. Importantly, the data support the potential for once-daily oral dosing and demonstrate clear target engagement of both TYK2 and JAK1. This reinforces Sareum’s positioning of SDC-1801 as a differentiated therapy for autoimmune diseases. The publication also supports the company’s ongoing Phase II-enabling activities (including formulation optimisation and the ongoing toxicology studies), with management targeting completion of the regulatory package by end-CY26.